Drug Class Segment Analysis: Prokinetic Agents (Largest Segment) vs Botulinum Toxin Injection (Fastest-Growing Segment)

Prokinetic agents held the largest share of the gastroparesis drugs market in 2026. Their leading position reflects their established role in improving gastrointestinal motility and addressing delayed gastric emptying, which is a central characteristic of gastroparesis. The broad clinical use of prokinetic therapies and their relevance to symptom management support continued demand among patients requiring pharmacological treatment. Growing recognition of gastroparesis and the need for therapies that target impaired gastrointestinal movement are reinforcing the segment's market position.

Botulinum toxin injection is emerging as the fastest-growing drug class as interest increases in alternative approaches for managing difficult-to-treat gastroparesis symptoms. Its localized administration and potential role in addressing gastrointestinal motility dysfunction are generating greater clinical interest in selected patient populations. Continued exploration of treatment options for patients who do not achieve adequate symptom relief through conventional approaches is supporting demand for alternative interventions, creating momentum for botulinum toxin injection.

Disease Type Segment Analysis: Diabetic Gastroparesis (Largest Segment) vs Idiopathic Gastroparesis (Fastest-Growing Segment)

Diabetic gastroparesis represented the largest disease type within the gastroparesis drugs market in 2026. Its leading position is closely associated with the relationship between diabetes and impaired gastrointestinal nerve and muscle function, which can contribute to delayed gastric emptying. The growing burden of diabetes and the need for ongoing management of associated complications create sustained demand for therapies addressing diabetic gastroparesis. Greater recognition of gastrointestinal complications among people with diabetes is also supporting diagnosis and treatment activity within this segment.

Idiopathic gastroparesis is advancing at the fastest pace as greater clinical attention is directed toward patients experiencing delayed gastric emptying without an identifiable underlying cause. Improving recognition and diagnosis of unexplained gastrointestinal motility disorders is expanding the addressable patient population for idiopathic gastroparesis therapies. The need for individualized symptom management and continued efforts to identify effective treatment approaches are supporting greater attention to this disease type. As diagnostic awareness improves, demand for therapies addressing idiopathic cases is expected to gain further momentum.